News
The solidarity campaign “Elles contra l’ELA” kicks off
The “Elles contra ELA” solidarity campaign begins today with the aim of raising awareness about ALS and raising funds for research. This project is promoted by the research group on neurological and neurogenetic diseases of the Bellvitge Biomedical Research Institute (IDIBELL), with the support of the Catalan Foundation of ALS Miquel Valls, the sponsorship of […]
A new system expands the gene-editing possibilities in animals
This new CRISPR-Cas9 tool can modify gene sites that were inaccessible until now, which bypasses the limited capabilities of gene editing and reinforce precision medicine.
IDIBELL researchers present a new recombinant protein that reverses the proinflammatory state of cells in patients with lupus
The protein can slow down the proinflammatory activity of the immune cells and, therefore, stop their body attack.
Begins the exchange program between IDIBELL and SZBL
It begins the selection of candidates to carry out a doctoral program in Regenerative Medicine between the SZBL and the IDIBELL. The program will run mainly at SZBL and will have a minimum six months stay at IDIBELL.
SARS-CoV-2 vaccines are safe and effective in people with immunodeficiency
The analysis show that these vaccines are safe and able to generate immunity in three out of four patients with immune system defects from birth, and in almost all patients treated with immunosuppressants who were evaluated in the study.
A clinical trial shows the safety and potential of an oncolytic virus against advanced pancreatic cancer
Preliminary results show that the virus is active, reaches the primary tumor and metastases, and triggers the immune system response. In addition, at recommended doses, it has no important adverse effects.
Psychosocial factors determine the effectiveness of self-care in patients with heart failure
Lack of family and social support and depressive symptoms are the main factors that impair patients’ ability to adopt healthy habits and practices.
The second edition of the project “VacunAcció: how to immunize yourself against misinformation” concludes
The initiative, promoted by the Escolab program and carried out by IDIBELL, has been carried out with 4th year ESO students from the Escola Pia of Granollers.
A study presents MCLA-158, the first drug candidate targeting cancer stem cells from solid tumors
An international consortium led by IRB Barcelona and the biotech company Merus, with the participation of IDIBELL and the Catalan Institute of Oncology, presents the preclinical data leading to the discovery of MCLA-158 and its action mechanism on cancer stem cells.